Dr. Untch on the Expanding Use of Biosimilars

Video

Michael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.

Michael Untch, MD, PhD, professor, chief physician, Obstetrics and Gynecology, Helios Hospital Berlin-Buch, Berlin, Germany, discusses the widespread use of biosimilars in Europe.

Following the introduction of ABP 980 (Kanjinti; trastuzumab-anns), a biosimilar for trastuzumab (Herceptin) over 1 year ago, biosimilars have gained traction in Germany, explains Untch. Now, several additional biosimilars for trastuzumab have been approved in Europe.

Biosimilars are used widely in Europe, says Untch. He suggests that the money saved from using biosimilars could be redirected to further research and therapeutic development for patients.

Although there is still some resistance toward biosimilars in the United States, Untch is certain their adoption in Europe will continue to expand as more biosimilars are introduced.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD